Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Beevers

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Hypertension|April 14, 2006
Quantification of topological changes in retinal vascular architecture in essential and malignant hypertensionAlun D Hughes, Elena Martinez-Perez, Abu-Sufian Jabbar, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
Blood Pressure|March 18, 2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE studyHenrik M Reims, Suzanne Oparil, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 6, 2009
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Hypertension|April 14, 2006
Quantification of topological changes in retinal vascular architecture in essential and malignant hypertensionAlun D Hughes, Elena Martinez-Perez, Abu-Sufian Jabbar, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
Blood Pressure|March 18, 2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE studyHenrik M Reims, Suzanne Oparil, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 6, 2009
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Pageof 8